Vol 10, Supp. A (2019)
Case report
Published online: 2019-04-26
Ruxolitinib treatment in a patient with primary myelofibrosis and thrombocytopenia
Abstract
46-years old male diagnosed with primary myelofibrosis (PMF) was included into therapeutic
program of treatment with ruxolitinib. Due to initial thrombocytopenia with basal platelets [PLT]
range below 100 G/l, initial dosage of the treatment was reduced according to characteristics of
drug. No treatment-related toxicity was noted, the dosage was gradually increased reaching the
dose 20 mg twice a day at twelfth week of therapy. Although alleviation of systemic symptoms was
reached, lack of diminishment of spleen size demanded by therapeutic program led to cessation of
treatment. In group of patients with PMF and secondary thrombocytopenia treatment with ruxolitinib
may lead to improvement of patient condition.
Keywords: primary myelofibrosismyelofibrosisthrombocytopeniaruxolitinib